Apnimed, the company behind what could become the first oral pharmacotherapy for obstructive sleep apnea (OSA), has filed for an initial public offering in the United States. The company is expected to list on Nasdaq under the ticker $APMD.
The filing comes at a notable moment for the biotech sector. After IPO activity plunged to its lowest level in more than a decade in 2025, fresh capital has started flowing back into the industry, and investor sentiment has begun to recover.
For sleep medicine professionals, though, the more consequential story may be what’s behind the filing. Apnimed’s lead candidate, AD109, is a once-daily pill taken at bedtime that pairs aroxybutynin, a novel antimuscarinic, with atomoxetine, a selective norepinephrine reuptake inhibitor. Rather than mechanically splinting the airway open, as PAP therapy and oral appliances do, the combination is designed to address the underlying neuromuscular cause of upper airway collapse during sleep.
AD109 met its primary endpoint in a second late-stage trial this past May, reinforcing earlier Phase 3 results and adding momentum heading into the IPO. Founded in 2017 and backed in part by Japan’s Shionogi & Co., Apnimed has already submitted a marketing application to the FDA and expects a decision in the first quarter of 2027.
An approval would land AD109 in a market where PAP therapy remains the gold standard but continues to struggle with adherence, a gap that helps explain why the majority of the estimated 80 million U.S. adults living with OSA remain undiagnosed, untreated, or inconsistently treated. Clinicians who have followed the program say a simple, well-tolerated oral option could change how patients are triaged, particularly those who have failed or declined device-based therapy.
Apnimed has not yet disclosed proposed pricing or share terms for the offering. SleepWorld Magazine will continue to track the IPO process alongside the FDA’s review of AD109 as the agency’s Q1 2027 decision date approaches.
Source: SleepWorld Magazine
